59 related articles for article (PubMed ID: 1818144)
1. A radiometric method for objectively screening large numbers of compounds against Pneumocystis carinii in vitro.
Comley JC; Mullin RJ; Wolfe LA; Hanlon MH; Ferone R
J Protozool; 1991; 38(6):144S-146S. PubMed ID: 1818144
[TBL] [Abstract][Full Text] [Related]
2. Microculture screening assay for primary in vitro evaluation of drugs against Pneumocystis carinii.
Comley JC; Mullin RJ; Wolfe LA; Hanlon MH; Ferone R
Antimicrob Agents Chemother; 1991 Oct; 35(10):1965-74. PubMed ID: 1759815
[TBL] [Abstract][Full Text] [Related]
3. Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations.
Piper JR; Johnson CA; Krauth CA; Carter RL; Hosmer CA; Queener SF; Borotz SE; Pfefferkorn ER
J Med Chem; 1996 Mar; 39(6):1271-80. PubMed ID: 8632434
[TBL] [Abstract][Full Text] [Related]
4. Characterization of de novo folate synthesis in Pneumocystis carinii and Toxoplasma gondii: potential for screening therapeutic agents.
Kovacs JA; Allegra CJ; Beaver J; Boarman D; Lewis M; Parrillo JE; Chabner B; Masur H
J Infect Dis; 1989 Aug; 160(2):312-20. PubMed ID: 2527275
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Pneumocystis carinii dihydropteroate synthetase by para-acetamidobenzoic acid: possible mechanism of action of isoprinosine in human immunodeficiency virus infection.
Kovacs JA; Powell F; Voeller D; Allegra CJ
Antimicrob Agents Chemother; 1993 Jun; 37(6):1227-31. PubMed ID: 7687120
[TBL] [Abstract][Full Text] [Related]
6. Anti-human immunodeficiency virus drugs are ineffective against Pneumocystis carinii in vitro and in vivo.
Walzer PD; Ashbaugh A; Collins M; Cushion MT
J Infect Dis; 2001 Nov; 184(10):1355-7. PubMed ID: 11679930
[TBL] [Abstract][Full Text] [Related]
7. Yeast glucan of Pneumocystis carinii cyst wall: an excellent target for chemotherapy.
Matsumoto Y; Yamada M; Amagai T
J Protozool; 1991; 38(6):6S-7S. PubMed ID: 1818205
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of pneumocystosis: preclinical evaluation].
Girard PM; Brun-Pascaud M; Roux P
Rev Pneumol Clin; 1991; 47(3):109-14. PubMed ID: 1957102
[TBL] [Abstract][Full Text] [Related]
9. Pteroylpolyglutamate synthesis by lung- and culture-derived Pneumocystis carinii.
Hong YL; Bartlett MS; Queener S; Smith JW; Shaw M; Meshnick SR
FEMS Microbiol Lett; 1995 Dec; 134(2-3):251-4. PubMed ID: 8586276
[TBL] [Abstract][Full Text] [Related]
10. Enhanced efficacy of a liposomal pentamidine preparation in Pneumocystis carinii in an ex vivo/in vitro culture model without feederlayer cells.
Sahm M; Wingen F; Hager J; Seitz HM
Appl Parasitol; 1996 Jun; 37(2):137-45. PubMed ID: 8688862
[TBL] [Abstract][Full Text] [Related]
11. Treatment and prevention of Pneumocystis carinii pneumonia and further elucidation of the P. carinii life cycle with 1,3-beta-glucan synthesis inhibitor L-671,329.
Schmatz DM; Powles M; McFadden DC; Pittarelli LA; Liberator PA; Anderson JW
J Protozool; 1991; 38(6):151S-153S. PubMed ID: 1818147
[TBL] [Abstract][Full Text] [Related]
12. Models for evaluating compounds for activity against Pneumocystis carinii.
Bartlett MS
Eur J Clin Microbiol Infect Dis; 1991 Mar; 10(3):199-201. PubMed ID: 2060530
[TBL] [Abstract][Full Text] [Related]
13. An ELISA method for quantitation of Pneumocystis carinii in culture and lung.
Durkin MM; Bartlett MS; Queener SF; Shaw MM; Lee CH; Smith JW
J Protozool; 1991; 38(6):208S-210S. PubMed ID: 1818173
[TBL] [Abstract][Full Text] [Related]
14. Biological profile and response to anti-pneumocystis agents of Pneumocystis carinii in cell culture.
Pifer LL; Pifer DD; Woods DR
Antimicrob Agents Chemother; 1983 Nov; 24(5):674-8. PubMed ID: 6607029
[TBL] [Abstract][Full Text] [Related]
15. Method of testing the susceptibility of Pneumocystis carinii to antimicrobial agents in vitro.
Cushion MT; Stanforth D; Linke MJ; Walzer PD
Antimicrob Agents Chemother; 1985 Dec; 28(6):796-801. PubMed ID: 3936409
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
Gangjee A; Adair OO; Queener SF
J Med Chem; 2003 Nov; 46(23):5074-82. PubMed ID: 14584957
[TBL] [Abstract][Full Text] [Related]
17. Extent of fungal contamination in rat-derived Pneumocystis carinii extracts and the effect on uptake of para-aminobenzoic acid.
Chung V; Shah K
J Eukaryot Microbiol; 1994; 41(5):80S-81S. PubMed ID: 7804277
[No Abstract] [Full Text] [Related]
18. Microtitre plate-based antibacterial assay incorporating resazurin as an indicator of cell growth, and its application in the in vitro antibacterial screening of phytochemicals.
Sarker SD; Nahar L; Kumarasamy Y
Methods; 2007 Aug; 42(4):321-4. PubMed ID: 17560319
[TBL] [Abstract][Full Text] [Related]
19. 2,4-diamino-5-deaza-6-substituted pyrido[2,3-d]pyrimidine antifolates as potent and selective nonclassical inhibitors of dihydrofolate reductases.
Gangjee A; Vasudevan A; Queener SF; Kisliuk RL
J Med Chem; 1996 Mar; 39(7):1438-46. PubMed ID: 8691474
[TBL] [Abstract][Full Text] [Related]
20. 2,5-bis[4-(N-alkylamidino)phenyl]furans as anti-Pneumocystis carinii agents.
Boykin DW; Kumar A; Xiao G; Wilson WD; Bender BC; McCurdy DR; Hall JE; Tidwell RR
J Med Chem; 1998 Jan; 41(1):124-9. PubMed ID: 9438029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
